lineomam lc
bioveta -
nityr
cycle pharmaceuticals (europe) ltd - nitizinon - tyrosinemias - drugi zdravljene bolezni prebavil in presnove izdelki, - za zdravljenje odraslih in pediatričnih bolnikih s potrjeno diagnozo dedno tyrosinemia tip 1 (ht-1) v kombinaciji z prehranskih omejitev tirozin in fenilalanin.
apivar
veto pharma sas 12 -
solamocta
eurovet animal health bv handelsweg 25 -
vantobra (previously tobramycin pari)
pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibacterials za sistemsko uporabo, - vantobra je označen za upravljanje kronično pljučno okužbo, zaradi pseudomonas aeruginosa pri bolnikih, starih 6 let in več, s cistično fibrozo (cf). upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.
xospata
astellas pharma europe b.v. - gilteritinib fumarate - leukemija, myeloid, akutna - antineoplastična sredstva - xospata je označen kot monotherapy za zdravljenje odraslih bolnikov, ki so relapsed ali ognjevzdržni akutno mieloično levkemijo (aml), z flt3 mutacija.
mirataz
dechra regulatory b.v. - mirtazapine - psychoanaleptics, antidepressants in combination with psycholeptics - mačke - za pridobivanje telesne teže pri mačkah slaba apetita in izguba teže, ki je posledica kroničnih obolenj.
arikayce liposomal
insmed netherlands b.v. - amikacin sulfate - okužbe dihalnih poti - antibacterials za sistemsko uporabo, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.
gavreto
roche registration gmbh - pralsetinib - karcinom, pljučni pljuč - antineoplastična sredstva - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
sapropterin dipharma
dipharma arzneimittel gmbh - sapropterin dihydrochloride - fenilketonurije - drugi zdravljene bolezni prebavil in presnove izdelki, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.